Press Releases May 15, 2026 06:30 AM

FTAI Aviation Announces Full Redemption of Outstanding 8.25% Fixed-Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares

FTAI Aviation Announces Redemption of Preferred Shares Series C at $25 Per Share

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
FTAI

FTAI Aviation Ltd. announced the full redemption of its outstanding 4,200,000 Series C cumulative perpetual redeemable preferred shares at $25 per share plus accumulated unpaid distributions, effective June 15, 2026. This follows their previous declaration of distributions payable on the redemption date. The Series C Shares trade under the ticker symbol FTAIN.

FTAI Aviation Announces Full Redemption of Outstanding 8.25% Fixed-Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares
FTAI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • FTAI Aviation is redeeming all 4.2 million outstanding Series C preferred shares at $25 per share in cash.
  • Distributions declared for the Series C shares payable on June 15, 2026, so no unpaid amounts will exist at redemption.
  • This move reflects a corporate finance action impacting FTAI Aviation’s capital structure potentially reducing preferred equity obligations.

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (NASDAQ: FTAI; “FTAI Aviation” or the “Company”) announced today that it will redeem all of the Company’s outstanding 4,200,000 8.25% Fixed-Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares (the “Series C Shares”) at a redemption price equal to $25.00 per Series C Share in cash, plus an amount equal to the accumulated and unpaid distributions thereon to, but not including, the redemption date of June 15, 2026 (the “Redemption”). The Company has previously declared distributions on the Series C Shares payable on June 15, 2026, thus no such amounts will be unpaid as of the Redemption. The Series C Shares trade under the ticker symbol “FTAIN.”

A Notice of Full Redemption for the Series C Shares describing the Redemption procedures was sent to holders of the Series C Shares on May 15, 2026. Additional information related to the Redemption procedures, including copies of the Notice of Full Redemption, may be obtained from Equiniti Trust Company, LLC by calling 718-921-8124 or 1-800-937-5449.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

ABOUT FTAI AVIATION

FTAI combines advanced turbine technology and asset ownership to power the world’s most essential markets. Additional information is available at https://www.ftaiaviation.com/.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the Redemption. These statements are based on management's current expectations and beliefs and are subject to a number of trends and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, many of which are beyond the Company’s control. The Company can give no assurance that its expectations will be attained and such differences may be material. Accordingly, you should not place undue reliance on any forward-looking statements contained in this press release. For a discussion of some of the risks and important factors that could affect such forward-looking statements, see the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available on the Company’s website (www.ftaiaviation.com). In addition, new risks and uncertainties emerge from time to time, and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results to differ from those contained in any forward-looking statements. Such forward-looking statements speak only as of the date of this press release. The Company expressly disclaims any obligation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or change in events, conditions, or circumstances on which any statement is based. Nothing on the Company’s website is included or incorporated by reference herein.

For further information, please contact:

Alan Andreini
Investor Relations
FTAI Aviation Ltd.
(646) 734-9414
aandreini@ftaiaviation.com

Media:

Tim Lynch / Aaron Palash / Kelly Sullivan
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449


Risks

  • Risk that market conditions or company cash flow might impact future redemption capability or necessitate use of liquidity affecting operational funding.
  • Potential uncertainties related to market reaction to the redemption possibly affecting investor perception and access to capital.
  • Broader economic or sector risks in the aviation and asset ownership industries could affect the company’s financial stability post-redemption.

More from Press Releases

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026